Clinical trials
Cataract trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
59 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 6 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 36 |
| Recruiting | 9 |
| Terminated | 8 |
| Unknown status | 4 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondation Ophtalmologique Adolphe de Rothschild | 8 |
| Assistance Publique - Hôpitaux de Paris | 5 |
| Centre Hospitalier Régional Metz-Thionville | 4 |
| Alcon Research | 3 |
| Beaver-Visitec International, Inc. | 3 |
| Johnson & Johnson Surgical Vision, Inc. | 3 |
| Cutting Edge SAS | 2 |
| Elsan | 2 |
| SIFI SpA | 2 |
| University Hospital, Montpellier | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cataract | 59 |
| Astigmatism | 3 |
| Glaucoma | 2 |
| Presbyopia | 2 |
| Vitreous Detachment | 2 |
| Alzheimer Disease | 1 |
| Aphakia | 1 |
| Aphakia, Postcataract | 1 |
| Bone Diseases, Metabolic | 1 |
| COVID-19 | 1 |
Trials
Showing 26 to 50 of 59. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.